Modeling ductal carcinoma in situ: A HER2-Notch3 collaboration enables luminal filling

Oncogene

Volumn 31, Issue 7, 2012, Pages 907-917

  Pradeep, C R ^a   Kostler W J ^a   Lauriola, M ^a   Granit, R Z ^b   Zhang, F ^c   Jacob Hirsch, J ^d   Rechavi, G ^d   Nair, H B ^e   Hennessy, B T ^c,f   Gonzalez Angulo, A M ^c,g   Tekmal, R R ^h   Ben Porath, I ^b   Mills, G B ^c   Domany, E ^a   Yarden, Y ^a,i  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d TEL AVIV UNIVERSITY   (Israel)

^e SOUTHWEST NATIONAL PRIMATE RESEARCH CENTER   (United States)

^f BEAUMONT HOSPITAL   (Ireland)

^g UNIVERSITY OF TEXAS   (United States)

^h UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

ⁱ MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

breast cancer; DCIS; growth factor; receptor tyrosine kinase; signal transduction; spheroids

Indexed keywords

CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MESSENGER RNA; MYC PROTEIN; NOTCH3 RECEPTOR; PROTEIN KINASE B; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR HES 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; BREAST EPITHELIUM; BREAST HYPERPLASIA; CANCER INHIBITION; CANCER MODEL; CANCER PATIENT; CANCER TISSUE; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; EPITHELIUM CELL; EXTRACELLULAR MATRIX; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; INTRACELLULAR SIGNALING; INTRADUCTAL CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN INDUCTION; TRANSCRIPTION REGULATION; UPREGULATION;

ANIMALS; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CELL LINE; CELL PROLIFERATION; EPIDERMAL GROWTH FACTOR; EPITHELIAL CELLS; FEMALE; GENE EXPRESSION PROFILING; GREEN FLUORESCENT PROTEINS; HEK293 CELLS; HUMANS; IMMUNOBLOTTING; MAMMARY GLANDS, HUMAN; MICE; MICE, TRANSGENIC; MICROSCOPY, CONFOCAL; MODELS, BIOLOGICAL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RECEPTOR, ERBB-2; RECEPTORS, NOTCH; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TRANSFECTION;

ANIMALIA;

EID: 84857112420     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.279     Document Type: Article

References (57)

1. Aranda V, Haire T, Nolan ME, Calarco JP, Rosenberg AZ, Fawcett JP et al. (2006). Par6-aPKC uncouples ErbB2 induced disruption of polarized epithelial organization from proliferation control. Nat Cell Biol 8: 1235-1245. (Pubitemid 44660588)
2. Bouchard L, Lamarre L, Tremblay PJ, Jolicoeur P. (1989). Stochastic appearance of mammary tumors in transgenic mice carrying the MMTV/c-neu oncogene. Cell 57: 931-936. (Pubitemid 19168373)
3. Bouras T, Pal B, Vaillant F, Harburg G, Asselin-Labat ML, Oakes SR et al. (2008). Notch signaling regulates mammary stem cell function and luminal cell-fate commitment. Cell Stem Cell 3: 429-441.
4. Chen Y, Fischer WH, Gill GN. (1997). Regulation of the ERBB-2 promoter by RBPJkappa and NOTCH. J Biol Chem 272: 14110-14114. (Pubitemid 27232816)
5. Clemenz AZ, Osipo C. (2009). Notch1 activates ErbB-2 through a PEA3-dependent mechanism. Cancer Res 69: 362s.
6. Cohen B, Shimizu M, Izrailit J, Ng NF, Buchman Y, Pan JG et al. (2010). Cyclin D1 is a direct target of JAG1-mediated Notch signaling in breast cancer. Breast Cancer Res Treat 123: 113-124.
7. Debnath J, Brugge JS. (2005). Modelling glandular epithelial cancers in three-dimensional cultures. Nat Rev Cancer 5: 675-688. (Pubitemid 41486361)
8. Debnath J, Mills KR, Collins NL, Reginato MJ, Muthuswamy SK, Brugge JS. (2002). The role of apoptosis in creating and maintaining luminal space within normal and oncogene-expressing mammary acini. Cell 111: 29-40.
9. Debnath J, Walker SJ, Brugge JS. (2003). Akt activation disrupts mammary acinar architecture and enhances proliferation in an mTOR-dependent manner. J Cell Biol 163: 315-326. (Pubitemid 37363132)
10. Desmedt C, Piette F, Loi S, Wang Y, Lallemand F, Haibe-Kains B et al. (2007). Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res 13: 3207-3214. (Pubitemid 46944903)
11. Dontu G, Abdallah WM, Foley JM, Jackson KW, Clarke MF, Kawamura MJ et al. (2003). In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev 17: 1253-1270. (Pubitemid 36583168)
12. Ellisen LW, Bird J, West DC, Soreng AL, Reynolds TC, Smith SD et al. (1991). TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell 66: 649-661. (Pubitemid 121001701)
13. Hennessy B, Lu Y, Gonzalez-Angulo AM, Carey MS, Myhre S, Ju Z et al. (2010). A technical assessment of the utility of reverse phase protein arrays for the study of the functional proteome in non-microdissected human breast cancers. Clinical Proteomics 6: 129-151.
14. Howlin J, McBryan J, Martin F. (2006). Pubertal mammary gland development: insights from mouse models. J Mammary Gland Biol Neoplasia 11: 283-297. (Pubitemid 44869922)
15. Hu C, Diévart A, Lupien M, Calvo E, Tremblay G, Jolicoeur P. (2006). Overexpression of activated murine Notch1 and Notch3 in transgenic mice blocks mammary gland development and induces mammary tumors. Am J Pathol 168: 973-990. (Pubitemid 43327749)
16. Hudziak RM, Lewis GD, Winget M, Fendly BM, Shepard HM, Ullrich A. (1989). p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol 9: 1165-1172. (Pubitemid 19071685)
17. Ignatiadis M, Desmedt C, Sotiriou C, de Azambuja E, Piccart M. (2009). HER-2 as a target for breast cancer therapy. Clin Cancer Res 15: 1848-1852.
18. Imatani A, Callahan R. (2000). Identification of a novel NOTCH-4/INT-3 RNA species encoding an activated gene product in certain human tumor cell lines. Oncogene 19: 223-231. (Pubitemid 30077218)
19. Iso T, Kedes L, Hamamori Y. (2003). HES and HERP families: multiple effectors of the Notch signaling pathway. J Cell Physiol 194: 237-255. (Pubitemid 36176887)
20. Jechlinger M, Podsypanina K, Varmus H. (2009). Regulation of transgenes in three-dimensional cultures of primary mouse mammary cells demonstrates oncogene dependence and identifies cells that survive deinduction. Genes Dev 23: 1677-1688.
21. Katz M, Amit I, Citri A, Shay T, Carvalho S, Lavi S et al. (2007). A reciprocal tensin-3-cten switch mediates EGF-driven mammary cell migration. Nat Cell Biol 9: 961-969. (Pubitemid 47190451)
22. Korkaya H, Paulson A, Iovino F, Wicha MS. (2008). HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion. Oncogene 27: 6120-6130.
23. Liu J, Sato C, Cerletti M, Wagers A. (2010). Notch signaling in the regulation of stem cell self-renewal and differentiation. Curr Top Dev Biol 92: 367-409.
24. Lonardo F, Di Marco E, King CR, Pierce JH, Segatto O, Aaronson SA et al. (1990). The normal erbB-2 product is an atypical receptorlike tyrosine kinase with constitutive activity in the absence of ligand. New Biol 2: 992-1003.
25. Magnifico A, Albano L, Campaner S, Delia D, Castiglioni F, Gasparini P et al. (2009). Tumor-initiating cells of HER2-positive carcinoma cell lines express the highest oncoprotein levels and are sensitive to trastuzumab. Clin Cancer Res 15: 2010-2021.
26. Mazzone M, Selfors LM, Albeck J, Overholtzer M, Sale S, Carroll DL et al. (2010). Dose-dependent induction of distinct phenotypic responses to Notch pathway activation in mammary epithelial cells. Proc Natl Acad Sci USA 107. 5012-5017.
27. Muthuswamy SK, Li D, Lelievre S, Bissell MJ, Brugge JS. (2001). ErbB2, but not ErbB1, reinitiates proliferation and induces luminal repopulation in epithelial acini. Nat Cell Biol 3: 785-792. (Pubitemid 32842683)
28. Nakayama K, Nakayama N, Jinawath N, Salani R, Kurman RJ, Shih IeM et al. (2007). Amplicon profiles in ovarian serous carcinomas. Int J Cancer 120: 2613-2617. (Pubitemid 46651282)
29. Palomero T, Dominguez M, Ferrando AA. (2008). The role of the PTEN/AKT Pathway in NOTCH1-induced leukemia. Cell Cycle 7: 965-970. (Pubitemid 351679827)
30. Palomero T, Lim WK, Odom DT, Sulis ML, Real PJ, Margolin A et al. (2006). NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth. Proc Natl Acad Sci USA 103: 18261-18266. (Pubitemid 44871646)
31. Palomero T, Sulis ML, Cortina M, Real PJ, Barnes K, CiofaniMet al. (2007). Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nat Med 13: 1203-1210. (Pubitemid 47530629)
32. Pece S, Serresi M, Santolini E, Capra M, Hulleman E, Galimberti V et al. (2004). Loss of negative regulation by Numb over Notch is relevant to human breast carcinogenesis. J Cell Biol 167: 215-221. (Pubitemid 39435065)
33. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA et al. (2000). Molecular portraits of human breast tumours. Nature 406: 747-752.
34. Pinkas-Kramarski R, Soussan L, Waterman H, Levkowitz G, Alroy I, Klapper L et al. (1996). Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J 15: 2452-2467. (Pubitemid 26151185)
35. Prigent SA, Gullick WJ. (1994). Identification of c-erbB-3 binding sites for phosphatidylinositol 30-kinase and SHC using an EGF receptor/c-erbB-3 chimera. EMBO J 13: 2831-2841.
36. Reedijk M, Odorcic S, Chang L, Zhang H, Miller N, McCready DR et al. (2005). High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival. Cancer Res 65: 8530-8537. (Pubitemid 41330622)
37. Schafer ZT, Grassian AR, Song L, Jiang Z, Gerhart-Hines Z, Irie HY et al. (2009). Antioxidant and oncogene rescue of metabolic defects caused by loss of matrix attachment. Nature 461: 109-113.
38. Schmidt M, Bohm D, von Torne C, Steiner E, Puhl A, Pilch H et al. (2008). The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res 68: 5405-5413.
39. Shackleton M, Vaillant F, Simpson KJ, Stingl J, Smyth GK, Asselin-Labat ML et al. (2006). Generation of a functional mammary gland from a single stem cell. Nature 439: 84-88. (Pubitemid 43053633)
40. Simpson CD, Anyiwe K, Schimmer AD. (2008). Anoikis resistance and tumor metastasis. Cancer Lett 272: 177-185.
41. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. (1987). Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182. (Pubitemid 17231334)
42. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A et al. (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783-792. (Pubitemid 32222155)
43. Speers C, Tsimelzon A, Sexton K, Herrick AM, Gutierrez C, Culhane A et al. (2009). Identification of novel kinase targets for the treatment of estrogen receptor-negative breast cancer. Clin Cancer Res 15: 6327-6340.
44. Sriuranpong V, Borges MW, Ravi RK, Arnold DR, Nelkin BD, Baylin SB et al. (2001). Notch signaling induces cell cycle arrest in small cell lung cancer cells. Cancer Res 61: 3200-3205. (Pubitemid 32691976)
45. Stingl J, Eirew P, Ricketson I, Shackleton M, Vaillant F, Choi D et al. (2006). Purification and unique properties of mammary epithelial stem cells. Nature 439: 993-997. (Pubitemid 43292419)
46. Stylianou S, Clarke RB, Brennan K. (2006). Aberrant activation of notch signaling in human breast cancer. Cancer Res 66: 1517-1525. (Pubitemid 43259933)
47. Tekmal RR, Nair HB, Perla RP, Kirma N. (2007). HER-2/neu x aromatase double transgenic mice model: the effects of aromatase overexpression on mammary tumorigenesis. J Steroid Biochem Mol Biol 106: 111-118. (Pubitemid 47362657)
48. Ueda Y, Wang S, Dumont N, Yi JY, Koh Y, Arteaga CL. (2004). Overexpression of HER2 (erbB2) in human breast epithelial cells unmasks transforming growth factor beta-induced cell motility. J Biol Chem 279: 24505-24513. (Pubitemid 38725316)
49. van de Vijver MJ, Peterse JL, Mooi WJ, Wisman P, Lomans J, Dalesio O et al. (1988). Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med 319: 1239-1245. (Pubitemid 18267063)
50. Wallasch C, Weiss FU, Niederfellner G, Jallal B, Issing W, Ullrich A. (1995). Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3. EMBO J 14: 4267-4275.
51. Weng AP, Ferrando AA, Lee W, Morris JPt, Silverman LB, Sanchez-Irizarry C et al. (2004). Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 306: 269-271. (Pubitemid 39336870)
52. Whelan JT, Forbes SL, Bertrand FE. (2007). CBF-1 (RBP-J kappa) binds to the PTEN promoter and regulates PTEN gene expression. Cell Cycle 6: 80-84. (Pubitemid 46173885)
53. Worthylake R, Opresko LK, Wiley HS. (1999). ErbB-2 amplification inhibits down-regulation and induces constitutive activation of both ErbB-2 and epidermal growth factor receptors. J Biol Chem 274: 8865-8874. (Pubitemid 29164687)
54. Yarden Y, Sliwkowski MX. (2001). Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2: 127-137. (Pubitemid 33674041)
55. Yin L, Velazquez OC, Liu ZJ. (2010). Notch signaling: emerging molecular targets for cancer therapy. Biochem Pharmacol 80: 690-701.
56. Zardawi SJ, Zardawi I, McNeil CM, Millar EK, McLeod D, Morey AL et al. (2010). High Notch1 protein expression is an early event in breast cancer development and is associated with the HER-2 molecular subtype. Histopathology 56: 286-296.
57. Zhan L, Xiang B, Muthuswamy SK. (2006). Controlled activation of ErbB1/ErbB2 heterodimers promote invasion of three-dimensional organized epithelia in an ErbB1-dependent manner: implications for progression of ErbB2-overexpressing tumors. Cancer Res 66: 5201-5208. (Pubitemid 43844943)